Topic - Nanopharm

Primary Crystallization’s Influence on Fluticasone DPIs

Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.

Explore predictions of regional deposition and systemic exposure of Albuterol Sulfate with low global warming potential propellants in pMDIs.

Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.

Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.

Explore Simulation-informed design in in-vitro bioequivalence trials for particle size distributions’ performance.

Nanopharm investigate the pulmonary effect of Fluticasone and related compounds, addressing physiologic and pharmacokinetic challenges.

Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).

Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.

Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.

Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.